People – Populus Bio

The right people to ask the right questions at the right time

Gertjan Bartlema

Gertjan thrives on building teams and creating collaborative impact. He is a pragmatic and authentic leader with broad operational experience.

Peter Greaney

Peter is a global deal-maker and is passionate about advancing innovative science for the benefit of patients.

Kevin Lynch

Kevin is a physician with more than 30 years industry experience and is inspired by the opportunity to develop transformative medicines for patients.

Gertjan Bartlema, thrives on building teams and creating collaborative impact. He is a pragmatic and authentic leader with broad operational experience. Gertjan most recently was the CEO of VICO Therapeutics BV a privately held Netherlands based company focused on antisense oligonucleotide-based RNA modulating therapeutics for rare CNS diseases. During his 20+ years global biotech career he was part of emerging organizations and new capabilities, including healthcare big data/real-world data and marketing & sales excellence capabilities. Under his leadership Celgene established an industry leading network of real-world data and technology partnerships including COTA, Inc., Flatiron Health, and GNS Healthcare and strategic partnerships with IBM Watson, Health2047, and M2Gen. Other roles he held during his career include Strategy, Business Development, Marketing & Sales Excellence, Business Planning and Financial Planning & Analysis. He started his biotech career at Amgen Europe as their first intern based in Lucerne, Switzerland. Gertjan holds a Masters in Economics from Maastricht University, the Netherlands and has dual Dutch and Swiss citizenship. He lives with his family in Switzerland.

Peter Greaney, PhD. is a global deal-maker and is passionate about advancing innovative science into clinical development for the benefit of patients. Peter has international experience in building successful biotech companies. He has been responsible for the successful execution of numerous business development deals in his career and has experience in a wide array of deal structures. He is experienced in seeking new business opportunities, leading negotiations, and managing research collaborations. At ADC Therapeutics, Peter was the Head of Corporate Development and played an integral role transforming the company from a private R&D biotech to a NYSE listed public biotech with a commercial therapeutic product. Prior to ADC Therapeutics, Peter held medical and business positions of increasing responsibility at Celgene in Switzerland and the United States. He held roles in Business Development, Strategy & Operations, Market Research & Business Intelligence, Medical Affairs, and Medical Development. Prior to Celgene, Peter was a Preclinical Senior Scientist at Apoxis, S.A. in Switzerland and an intern scientist at Servier, Paris. Peter graduated with a Bachelor of Science in Cell Biology from the University of East Anglia and a PhD in Molecular and Cellular Biology from the University of Nottingham (supported by Servier).

Kevin Lynch, MD. is inspired by developing transformative medicines for patients. He has lived and worked in Australia, Asia, UK and Switzerland, operating in both small, start-up environments as well as large, multi-nationals. Kevin was Chief Medical Expert during Antengene’s formative years and then through a period of extreme growth as Chief Medical Officer. He supervised their broad clinical program with Xpovio (Selinexor) in Asia-Pacific, as well as an extensive first-in-human early development program. During over 11 years at Celgene Kevin was closely involved in the successful clinical development and registration of Revlimid (lenalidomide), Pomalyst (pomalidomide), Vidaza (azacitidine), Onureg (oral azacitidine) and Idhifa (enasidinib). During his 10 years with Novartis, as one of the inaugural Oncology Medical Directors for the company, he played a key role in the development and approvals of multiple transformative drugs including Glivec (imatinib), Tasigna (nilotinib), Zometa (zoledronic acid), Femara (letrozole) and Exjade (deferasirox). Kevin graduated B Med Sci and MB, BS from the University of Tasmania in Australia. His post-graduate training in Pharmaceutical Medicine was completed in the UK, where he gained his Fellowship of the Faculty of Pharmaceutical Medicine.

People Make the Difference

Bespoke and rapidly available network of industry leading experts, tailored to each project needs

T.E.A.M. together everyone achieves more

* representative sample